Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) has made headway across its gene therapy pipeline, reporting strong mid-year momentum in its programmes targeting age-related diseases, muscle loss, and degenerative eye conditions.
The update also highlighted important developments in intellectual property and new strategic collaborations.
The London-listed biotech, which specialises in therapies based on a centenarian variant of the SIRT6 gene, has struck new partnerships with Belgian research centre CER Groupe and medical artificial intelligence firm Heureka Labs, a spin-out from Duke University.
These moves are expected to strengthen Genflow’s research and development infrastructure as it prepares for upcoming clinical trial applications.
In parallel, Genflow has expanded its global patent footprint, with its core SIRT6 application advancing through key stages in both Europe and Japan.
It has also applied for further grant funding to support filings across the US, Canada, Australia and China.
Within its therapeutic pipeline, the company said manufacturing tests for its lead candidate GF-1002, targeting metabolic dysfunction-associated steatohepatitis (MASH), exceeded expectations. It is now running pivotal studies to support regulatory filings.
Other programmes have also moved forward. Genflow has begun a clinical trial in ageing dogs, is refining a muscle-loss treatment using dual-gene technology, and has launched an ophthalmology initiative aimed at tackling glaucoma and corneal disease using non-viral gene delivery.
Across all its projects, Genflow said it remains focused on high-precision, ethically sound research, with several programmes supported by grants from the Walloon government in Belgium.